Trial Profile
Treatment of Chronic Hepatitis C With PegIntron [peginterferon alfa-2b] Injector and Rebetol [ribavirin] According to German Law (67 Abs 6 AMG)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2008 Planned number of patients changed to 2211.
- 17 Dec 2008 Planned end date changed from 1 Jan 2009 to 1 Jun 2009.